Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The closing price of Oruka Therapeutics Inc (NASDAQ: ORKA) was $27.91 for the day, up 1.56% from the previous closing price of $27.48. In other words, the price has increased by $1.56 from its previous closing price. On the day, 0.66 million shares were traded. ORKA stock price reached its highest trading level at $29.1881 during the session, while it also had its lowest trading level at $26.835.
Ratios:
Our analysis of ORKA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 27.42 and its Current Ratio is at 27.42. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Barclays on October 13, 2025, initiated with a Overweight rating and assigned the stock a target price of $48.
On May 22, 2025, BTIG Research started tracking the stock assigning a Buy rating and target price of $44.
On February 04, 2025, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $20.Wolfe Research initiated its Outperform rating on February 04, 2025, with a $20 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 14 ’25 when Venrock Healthcare Capital Par bought 88,794 shares for $11.44 per share. The transaction valued at 1,015,803 led to the insider holds 4,148,428 shares of the business.
Venrock Healthcare Capital Par bought 14,950 shares of ORKA for $173,868 on Feb 13 ’25. The 10% Owner now owns 4,059,634 shares after completing the transaction at $11.63 per share. On Feb 12 ’25, another insider, Venrock Healthcare Capital Par, who serves as the 10% Owner of the company, bought 8,971 shares for $11.86 each. As a result, the insider paid 106,396 and bolstered with 4,044,684 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ORKA now has a Market Capitalization of 1350401664 and an Enterprise Value of 722101312.
Stock Price History:
The Beta on a monthly basis for ORKA is -0.39, which has changed by -0.031239152 over the last 52 weeks, in comparison to a change of 0.14201736 over the same period for the S&P500. Over the past 52 weeks, ORKA has reached a high of $31.13, while it has fallen to a 52-week low of $5.49. The 50-Day Moving Average of the stock is 63.90%, while the 200-Day Moving Average is calculated to be 110.44%.
Shares Statistics:
ORKA traded an average of 311.83K shares per day over the past three months and 598020 shares per day over the past ten days. A total of 48.38M shares are outstanding, with a floating share count of 42.06M. Insiders hold about 13.06% of the company’s shares, while institutions hold 67.20% stake in the company. Shares short for ORKA as of 1759190400 were 3613897 with a Short Ratio of 11.59, compared to 1756425600 on 3197757. Therefore, it implies a Short% of Shares Outstanding of 3613897 and a Short% of Float of 10.5299994.
Earnings Estimates
. The current market rating for Oruka Therapeutics Inc (ORKA) reflects the collective analysis of 5.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.59, with high estimates of -$0.4 and low estimates of -$0.7.
Analysts are recommending an EPS of between -$1.48 and -$2.33 for the fiscal current year, implying an average EPS of -$2.03. EPS for the following year is -$2.23, with 5.0 analysts recommending between -$1.79 and -$2.77.
